v3.24.4
Consolidated Statements of Shareholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Preferred Stock [Member]
Comprehensive Income [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2021 $ 1 $ 32,789,974 $ 100,000 $ (23,139) $ (32,655,174) $ 211,662
Beginning balance, shares at Dec. 31, 2021 1,296   1,000,000      
Fractional shares issued for reverse stock split
Fractional shares issued for reverse stock split, shares 2          
Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs $ 3 30,367,182 30,367,185
Common stock and pre-funded warrants issued in public and private offerings, net of issuance costs, shares 3,328          
Exercise of warrants $ 5 13,193,172 13,193,177
Exercise of warrants, shares 4,817          
Preferred stock purchased from related party $ (99,000) (99,000)
Preferred stock purchased from related party, shares     (990,000)      
Common stock issued as part of Nora Pharma acquisition $ 2 4,513,998 4,514,000
Common stock issued as part of Nora Pharma acquisition, shares 1,850          
Net (loss) 184,986 (26,744,440) (26,559,454)
Ending balance, value at Dec. 31, 2022 $ 11 80,864,326 $ 1,000 161,847 (59,399,614) 21,627,570
Ending balance, shares at Dec. 31, 2022 11,293   10,000      
Repurchase of treasury stock (541,143) (541,143)
Repurchase of treasury stock, shares (257)          
Common stock and pre-funded warrants issued in a private offering net of expenses $ 1 4,089,217 4,089,218
Common stock and pre-funded warrants issued in a private offering net of expenses, shares 1,225          
Exercise of warrants $ 2 3,500 3,502
Exercise of warrants, shares 1,751          
Net (loss) 534,258 (4,506,044) (3,971,786)
Ending balance, value at Dec. 31, 2023 $ 14 $ 84,415,900 $ 1,000 $ 696,105 $ (63,905,658) $ 21,207,361
Ending balance, shares at Dec. 31, 2023 14,012   10,000